Test of HB0036 for advanced cancers that ran out of options
Part of Cancer clinical trials.
This early-phase study tests whether HB0036 is safe and can work in people with advanced solid tumors (cancers) that have come back or spread and did not respond to standard treatments. You may be considered especially if your tumor matches certain tumor types and biomarker results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and can take part in study visits and tests.
- You have advanced solid cancer (locally advanced, recurrent, or metastatic) that has failed standard treatments; for some people, liver cancer may qualify if diagnosed clinically.
- For the NSCLC (lung cancer) group: your tumor must be PD-L1 positive (TPS 1% or higher) and you should not have certain known “targetable” gene changes like EGFR or ALK.
- You must have at least one measurable tumor spot on CT or MRI (based on size rules), and it must not have been newly treated with radiation unless it grew after treatment.
- Your overall health markers must be good enough for treatment (blood counts, kidney, liver, and clotting tests), and you must be able to function day-to-day (ECOG 0–1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests MHB036C in people with advanced or metastatic solid cancers that have stopped responding to standard treatments (or no standard options exist). It is meant to see how the drug works and how safe it is in this group.
This Phase 1 trial tests HS-10386 (an experimental treatment) in people with advanced solid tumors that can’t be cured with standard options. The goal is to find a safe dose and see how the cancer responds.
This study tests a new drug called HC006 for advanced solid tumors that no longer respond to standard treatments. It aims to find a safe dose and see if it helps shrink tumors.
This trial tests a new drug called PLB-002 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, especially for cancers that show a specific marker called CLDN6.
This early-phase trial tests NB002, a new immune-targeting medicine, to find safe doses and see how well it can treat advanced or metastatic solid cancers that have not responded to standard treatments. It may help by strengthening the immune system’s ability to fight the tumor.
This early-phase trial tests a new oral targeted drug, ND-003, for people with advanced solid tumors that have not responded to standard therapy. The study focuses on tumors with specific gene changes (NTRK or RET fusions), especially in the second part, to see if the drug can shrink tumors and be safe.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.